Headline: Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Location: Dublin, Ireland
Post Date: Jul 13, 2020 8:04 AM
TAG ID: pznewsml314729
DocID: 202007137958286-en.newsml
Word Count: approx. 924 words
 
Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with NarcolepsyAvadel
 
Please login to download this Story